SCHEMBL10272928

SCHEMBL10272928

CCc1cc(-c2cccnc2)ncn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.55
CYP3A4 P08684 11/20 0.54
CYP1A2 P05177 9/20 0.54
CLK4 Q9HAZ1 7/20 0.54
CYP2C19 P33261 6/20 0.54
HSD17B10 Q99714 6/20 0.54
CYP2D6 P10635 6/20 0.54
TSHR P16473 2/20 0.54
ALOX15 P16050 2/20 0.54
CYP2A6 P11509 6/20 0.53
CYP2E1 P05181 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2B6 P20813 2/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10271328 0.81 KMT2A (0.56) KMOCYP3A4CYP1A2CYP2C19HSD17B10
SCHEMBL12259757 0.80 MAP4K4 (0.41) CYP3A4CYP1A2CYP2C19HSD17B10CYP2D6
SCHEMBL6844957 0.78 CYP2A6 (0.62) KMOCYP3A4CYP1A2CLK4CYP2C19
SCHEMBL18905235 0.78 KMO (0.68) KMOCYP3A4CYP1A2CLK4CYP2C19
SCHEMBL13436016 0.77 CYP2A6 (0.53) CYP3A4CYP1A2CLK4CYP2C19CYP2D6
SCHEMBL10272457 0.77 CYP2A6 (0.52) CYP3A4CYP1A2CYP2C19CYP2D6CYP2A6
SCHEMBL19513369 0.75 LOXL2 (0.71) KMOCYP3A4CYP1A2CLK4CYP2C19
SCHEMBL24151512 0.75 KMO (0.59) KMOCYP3A4CYP1A2CLK4CYP2C19
SCHEMBL10272816 0.75 PIM1 (0.40) CYP1A2CYP2C19CYP2D6TSHRCYP2C9
SCHEMBL558195 0.75 ASIC3 (0.65) KMOCYP3A4CYP1A2CLK4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-23 US disclosed
US-8278320-B2 Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-02 US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-20110263605-A1 Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KMO 932/4885CYP3A4 2815/4885CYP1A2 2027/4885
US-20110263605-A1 Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA2, CHRNA5 KMO 482/4885CYP3A4 2061/4885CYP1A2 593/4885
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KMO 932/4885CYP3A4 2815/4885CYP1A2 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.